9 completed, 8 terminated, 2 recruiting, 2 withdrawn. 23 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 9, Terminated 8, Recruiting 2, Withdrawn 2, Active not recruiting 1, Suspended 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
Follow INC280: new trials by email Literature Review of INC280 trials Research Report on INC280
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 66 | 2023-05-05 | 2026-06-03 |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC capmatinib - Non-small Cell Lung Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 4 | 2022-08-10 | 2025-10-16 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 90 | 2022-03-22 | 2023-02-03 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2021-05-17 | 2026-03-31 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2020-08-19 | 2024-10-09 |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% Capmatinib, Pembrolizumab - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Novartis Pharmaceuticals | 76 | 2020-01-22 | 2024-10-09 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Capmatinib, Spartalizumab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Novartis Pharmaceuticals | 18 | 2018-12-26 | 2022-01-24 |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma PDR001, LAG525, INC280 - Melanoma | Phase 2 | Completed | Novartis Pharmaceuticals | 196 | 2018-09-10 | 2024-06-18 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) INC280 - Carcinoma, Non-Small-Cell Lung Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-07-31 | 2018-07-26 | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone Capmatinib, Nazartinib, Gefitinib - Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 29 | 2017-07-04 | 2026-09-09 |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma INC280, Placebo - Advanced Hepatocellular Carcinoma | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-12-01 | 2016-09-01 | |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Spartalizumab, Capmatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 89 | 2016-06-15 | 2023-07-03 |
| Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Capmatinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Novartis Pharmaceuticals | 373 | 2015-06-11 | 2024-03-20 |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Capmatinib, Ceritinib, Entrectinib - ALK Fusion Protein Expression, BRAF wt Allele | Phase 2 | Terminated | University of California, San Francisco | 1 | 2015-03-26 | 2020-01-27 |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer EGF816, INC280, Nivolumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 64 | 2015-02-09 | 2022-02-28 |
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer BYL719, INC280, LDK378 - Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 66 | 2015-01-20 | 2020-12-16 |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. Capmatinib, Nazartinib - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 177 | 2015-01-13 | 2023-06-18 |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma LGX818, MEK162, LEE011 - Melanoma | Phase 2 | Completed | Pfizer | 158 | 2014-07-23 | 2024-03-05 |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer INC280 - Kidney Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2014-01-24 | 2023-03-21 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Adenocarcinoma of Lung (4) · Lung Neoplasms (4) · Melanoma (3) · Neoplasm Metastasis (2) · Adenocarcinoma Of Esophagus (1) · Brain Neoplasms (1) · Carcinoma (1) · Glioblastoma (1) · Gliosarcoma (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Neoplasms (1) · Noonan Syndrome 6 (1)
Novartis Pharmaceuticals (17) · Assistance Publique - Hôpitaux de Paris (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · SWOG Cancer Research Network (1) · University of California, San Francisco (1)
United States (14) · France (13) · Germany (13) · Spain (13) · Italy (11) · Australia (7) · Canada (7) · Netherlands (7) · Belgium (6) · China (6) · Singapore (6) · South Korea (6) · Switzerland (5) · Taiwan (5) · Hong Kong (4)
Adil Daud (1) · Birgit Geoerger, MD (1) · Ramaprasad Srinivasan, M.D. (1) · Sarah B Goldberg (1)
PMID 26825170, PMID 30156984, PMID 31538815, PMID 31776899, PMID 31853265, PMID 32877583, PMID 33892407, PMID 34347542, PMID 34376578, PMID 34543871, PMID 35292802, PMID 36822130, PMID 38617599, PMID 38763104, PMID 38986421, PMID 39362249, PMID 41838385, PMID 41914670, PMID 42686334
2014 (3), 2018 (2), 2019 (2), 2015 (1), 2016 (1), U10CA180888 (1)